Abstract

The esophageal gland duct may serve as a pathway for the spread of early esophageal squamous cell neoplasia (ESCN) to a deeper layer. Deep intraductal tumor spreading cannot be completely eradicated by ablation therapy. However, the risk factors of ductal involvement (DI) in patients with ESCNs have yet to be investigated. We consecutively enrolled 160 early ESCNs, which were treated with endoscopic submucosal dissection. The resected specimens were reviewed for the number, morphology, resected margin, distribution and extension level of DI, which were then correlated to clinical factors. A total of 317 DIs (median:3, range 1–40 per-lesion) in 61 lesions (38.1%) were identified. Of these lesions, 14 have DIs maximally extended to the level of lamina propria mucosa, 17 to muscularis mucosae, and 30 to the submucosa. Multivariate logistic regression analysis showed that tumors located in the upper esophagus (OR = 2.93, 95% CI, 1.02–8.42), large tumor circumferential extension (OR = 5.39, 95% CI, 1.06–27.47), deep tumor invasion depth (OR = 4.12, 95% CI, 1.81–9.33) and numerous Lugol-voiding lesions in background esophageal mucosa (OR = 2.65, 95% CI, 1.10–6.37) were risk factors for DI. The maximally extended level of ducts involved were significantly correlated with the cancer invasion depth (P < 0.05). Notably, 245 (77%) of the involved ducts were located at the central-trisection of the lesions, and 52% of them (165/317) revealed dilatation of esophageal glandular ducts. Five (1.6%) of the involved ducts revealed cancer cell invasion through the glandular structures. In conclusion, DI is not uncommon in early ESCN and may be a major limitation of endoscopic ablation therapy.

Highlights

  • The esophageal gland duct may serve as a pathway for the spread of early esophageal squamous cell neoplasia (ESCN) to a deeper layer

  • A total of 160 early-stage esophageal squamous neoplasias were treated with Endoscopic submucosal dissection (ESD)

  • Multivariate logistic regression analysis showed that tumors located in the upper esophagus (OR = 2.93, 95% CI, 1.02–8.42), large tumor circumferential extension (OR = 5.39, 95% CI, 1.06–27.47), pre-treatment histology with SCC (OR = 4.12, 95% CI, 1.81–9.33) and numerous Lugol-voiding lesions (LVLs) in background esophageal mucosa (OR = 2.65, 95% CI, 1.10–6.37) were predictors of esophageal ductal involvement (DI) (Table 2)

Read more

Summary

Introduction

The esophageal gland duct may serve as a pathway for the spread of early esophageal squamous cell neoplasia (ESCN) to a deeper layer. The risk factors of ductal involvement (DI) in patients with ESCNs have yet to be investigated. The maximally extended level of ducts involved were significantly correlated with the cancer invasion depth (P < 0.05). In cases with early ESCN, the ducts of submucosal gland may serve as a path for tumor to spread to www.nature.com/scientificreports a deeper layer, so-called ductal involvement (DI)[11,12,13]. Because the maximal ablation depth of RFA in esophagus is the muscularis mucosae layer[14], the deep intraductal tumor spreading could not be completely eradicated, which may potentially lead to tumor recurrence or even buried cancer. This study aimed to investigate the clinical predictors and pathological characteristics of DI with the aim of guiding management and choosing the most appropriate endoscopic modality

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call